Anzeige
Mehr »
Donnerstag, 09.07.2026 - Börsentäglich über 12.000 News
Paukenschlag! Diese Gratis-Aktien könnten jetzt Gold wert sein
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
174 Leser
Artikel bewerten:
(1)

TailorMed and Tennr Announce Collaboration to Streamline Patient Medication Workflows

Collaboration connects referral automation and medication journey support for infusion centers, specialty pharmacies, and the patients they serve

NEW YORK, NY / ACCESS Newswire / July 9, 2026 / TailorMed, a leading medication success platform, and Tennr, the patient orchestration platform that moves patients from script to seat, today announced a collaboration designed to help infusion centers and specialty pharmacies streamline patient access, affordability, and adherence workflows. The collaboration brings together two advanced technology platforms focused on reducing burden for care teams and their patients. Tennr helps providers automate referral intake, documentation review, and access-related workflows, while TailorMed helps organizations identify, manage, and optimize medication affordability and ongoing support opportunities for patients across the entire care journey.

The companies will begin with an integration, with Pure Infusion as the first customer, that will create a more connected access infrastructure so teams can identify care barriers earlier and move patients toward treatment faster.

"Our work has always been about getting patients care faster," said Trey Holterman, CEO of Tennr. "We exist to get patients care before they fall into the infamous black hole of U.S. healthcare. The biggest reason we see patients not getting access to medication is fear and uncertainty around what the medication will cost them personally and what resources they have at their disposal to cover those costs. With Tennr and TailorMed, we can call and give patients all the financial information they'll need. "

"Getting a patient referred and empowering them to succeed in their medication journey are two halves of the same problem," said Srulik Dvorsky, CEO of TailorMed. "Tennr has built remarkable technology for the first half and we've built a vast network and robust solution set for the second. Bringing the pieces together means fewer patients falling in the gap between a referral and the start of care."

"Our patients need to access care quickly, barrier-free," said Brady Porter, Chief Commercial Officer, at Pure Infusion. "Working with Tennr and TailorMed lets our team move patients from referral to treatment faster, with less friction and more confidence."

The collaboration reflects a broader movement in healthcare toward connected technology infrastructure that supports care teams and patients across traditionally fragmented access, intake, affordability, and adherence workflows.

About TailorMed
TailorMed is the medication success platform removing every barrier across the patient medication journey, from access and affordability through adherence and ongoing care. Through a connected network spanning 945+ hospitals, 4,700+ clinics, 3,100+ pharmacies, 100+ life sciences programs, and 6,000+ support programs, TailorMed reaches 75 million patients and has secured more than $7.4 billion in financial assistance since 2020. TailorMed's platform connects providers, pharmacies, patients, and life sciences companies through one coordinated infrastructure designed to reach every patient at every step of their medication journey. Learn more at tailormed.com.

About Tennr
Founded by Stanford alums, Tennr has raised over $160 million from IVP, Andreessen Horowitz, Lightspeed, GV, ICONIQ, Foundation Capital, and Frank Slootman with the purpose of eliminating patient care delays across the U.S. by helping healthcare providers get patients the right care, at the right time, in the right setting. Tennr.com

Media Contacts
TailorMed:
Jennifer Martin jenm@tailormed.co

Glenn Goldberg
Parallel Communications Group
+1 516 776-3282
ggoldberg@parallelpr.com

Tennr:
Maddie Buras maddie@tennr.com

SOURCE: TailorMed



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/tailormed-and-tennr-announce-collaboration-to-streamline-patient-medi-1188899

© 2026 ACCESS Newswire
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.